ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 342

Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study

Brigitte Michelsen1,2, Till Uhlig1, Eirik K Kristianslund1, Joseph Sexton1, Elisabeth Lie1, Karen M Fagerli3, Hilde B Hammer4, Glenn Haugeberg5,6 and Tore K Kvien7, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Martina Hansens Hospital, Bærum, Norway, 6NTNU, Norwegian University of Science and Technology, Trondheim, Norway, 7Diakonhjemmet Hospital, Oslo, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Health Assessment Questionnaire, Health outcome, Psoriatic arthritis, Quality measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 5, 2017

Session Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

It is well established that RA patients have lower health related quality of life (HRQoL) across several domains compared with the general population, whereas less is known about PsA patients.

The aim of this study was to compare the Medical Outcomes Survey Short Form-36 (SF-36) Physical and Mental Component Summaries (PCS, MCS) as well as domain scores between RA and PsA patients from a large prospective observational registry.

 

Methods:

We included first-time enrolled RA and PsA patients from the prospective observational multicenter NORwegian-Disease Modifying Anti-Rheumatic Drug (NOR-DMARD) study, starting synthetic and biologic DMARDs between year 2000 and 2012. Continuous variables were compared using independent t-test or Mann-Whitney U-test, as appropriate. Prespecified ANCOVA analyses adjusted for age, gender and disease duration were performed to compare the SF-36 domains between RA and PsA patients at baseline and after 3 months follow-up. Spyder diagram was made to visualize the differences in health domains (0 worst, 100 best) between the RA and PsA patients.

 

Results:

A total of 3903 RA and 1518 PsA patients were included (mean (SD) age 56.8 (31.6)/ 47.9 (12.6) years, median (25th-75th percentile) disease duration 1.9 (0.07-11.0)/ 2.0 (0.12-9.6) years, 71.2%/ 50.2% women). Mean (SD) 28-joint Disease Activity Score was higher in RA vs. PsA patients at baseline (4.9 (1.4)/ 4.2 (1.3)) and at 3 months (3.8 (1.5)/ (3.3 (1.4)) follow-up (p≤0.001).  Unadjusted means and adjusted estimated marginal means of PCS, MCS and domain scores all improved during follow-up (table, figure). In adjusted analyses PCS and MCS were similar between the RA and PsA patients. However, RA patients had slightly worse physical function and role emotional domains and PsA patients had slightly worse general health and vitality domains both at baseline and at 3 months. Bodily pain was similar between RA and PsA patients at baseline, but slightly worse in the PsA patients at 3 months follow-up.

 

Conclusion:

Levels of HRQoL were comparable across all SF-36 domains and component summary scores between patients with RA and PsA, in spite of higher levels of joint inflammation in the RA patients.

 

 

Table   Unadjusted and adjusted analyses of SF-36 component summary and domain scores

 

Summary score/ domain

Unadjusted analyses, mean (SD)

p-value1

Estimated marginal means (95%CI)

p-value2

RA

PsA

RA

PsA

Baseline

Physical Component Summary

31.0 (9.9)

31.8 (9.5)

0.01

31.7 (31.3-32.0)

31.6 (31.1-32.1)

0.88

Mental Component Summary

46.0 (11.4)

46.3 (11.5)

0.31

46.4 (46.0-46.8)

46.3 (45.7-46.8)

0.72

Physical Function

49.7 (25.0)

54.5 (23.4)

<0.001

51.6 (50.8-52.4)

53.9 (52.7-55.2)

0.002

Role Physical

20.0 (31.6)

23.7 (34.1)

<0.001

21.4 (20.3-22.5)

23.4 (21.8-25.1)

0.04

Bodily Pain

34.5 (19.0)

34.7 (18.2)

0.77

35.4 (34.8-36.1)

34.5 (33.6-35.5)

0.13

General Health

51.1 (20.3)

49.4 (20.7)

0.006

51.7 (51.1-52.4)

49.2 (48.2-50.3)

<0.001

Vitality

39.2 (20.5)

38.7 (20.9)

0.39

41.1 (40.4-41.8)

38.6 (37.6-39.7)

<0.001

Social Functioning

63.9 (26.4)

64.8 (25.8)

0.28

65.5 (64.6-66.4)

64.7 (63.4-66.0)

0.34

Role Emotional

51.4 (42.9)

55.8 (42.9)

0.001

52.3 (50.9-53.8)

55.3 (53.1-57.4)

0.03

Mental Health

70.0 (18.3)

70.6 (17.7)

0.31

71.0 (70.3-71.6)

70.6 (69.7-71.5)

0.52

3 Months

Physical Component Summary

35.6 (11.1)

36.4 (10.8)

0.06

36.4 (36.0-36.8)

36.1 (35.5-36.7)

0.54

Mental Component Summary

48.1 (10.9)

48.1 (11.3)

0.98

48.2 (47.8-48.6)

48.0 (47.3-48.6)

0.55

Physical Function

57.6 (25.9)

62.1 (24.3)

<0.001

59.6 (58.7-60.6)

61.4 (60.0-62.8)

0.04

Role Physical

34.5 (38.9)

38.3 (39.5)

0.003

35.9 (34.4-37.4)

37.5 (35.3-39.7)

0.23

Bodily Pain

49.0 (22.0)

47.9 (21.3)

0.12

49.8 (49.0-50.6)

47.5 (46.3-48.8)

0.002

General Health

54.2 (21.2)

53.1 (21.7)

0.14

54.8 (54.0-55.6)

52.9 (51.6-54.1)

0.009

Vitality

46.7 (21.5)

45.0 (21.1)

0.02

48.1 (47.3-48.9)

44.8 (43.6-46.0)

<0.001

Social Functioning

71.8 (24.7)

72.2 (24.8)

0.68

73.0 (72.0-73.9)

71.8 (70.4-73.2)

0.19

Role Emotional

59.7 (41.4)

64.0 (40.9)

0.002

60.0 (58.4-61.5)

63.0 (60.7-65.4)

0.03

Mental Health

74.2 (17.3)

74.1 (17.1)

0.84

74.8 (74.2-75.5)

73.9 (73.0-74.9)

0.15

1 Independent t-test; 2ANCOVA adjusted for age, gender and disease duration

 

Figure Estimated marginal means adjusted for age, gender and disease duration of baseline and 3 months SF-36 domains

 


Disclosure: B. Michelsen, None; T. Uhlig, None; E. K. Kristianslund, None; J. Sexton, None; E. Lie, AbbVie, Celgene, Hospira and Pfizer, 8; K. M. Fagerli, None; H. B. Hammer, AbbVie Norway, 2,Abbvie, 8,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 8,Roche Pharmaceuticals, 8; G. Haugeberg, None; T. K. Kvien, AbbVie, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,UCB, 2,BMS, 2,MSD, 2,AbbVie, 5,Pfizer Inc, 5,BMS, 8,MSD, 8,Roche Pharmaceuticals, 8,UCB, 8,AbbVie, 8.

To cite this abstract in AMA style:

Michelsen B, Uhlig T, Kristianslund EK, Sexton J, Lie E, Fagerli KM, Hammer HB, Haugeberg G, Kvien TK. Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/health-related-quality-of-life-is-comparable-in-psoriatic-arthritis-and-rheumatoid-arthritis-patients-in-spite-of-different-disease-activity-sf-36-data-from-a-large-prospective-observational-mul/. Accessed February 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/health-related-quality-of-life-is-comparable-in-psoriatic-arthritis-and-rheumatoid-arthritis-patients-in-spite-of-different-disease-activity-sf-36-data-from-a-large-prospective-observational-mul/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.